OncoSec featured in Seattle-based newspaper

OncoSec Medical (OTC:ONCS) said Wednesday lead investigator Shailender Bhatia was featured in The Journal Newspaper, a local Seattle news outlet.

The biomedical company, founded in 2011, develops advance-stage ElectroOncology anti-cancer therapies to treat people with solid tumours.

Bhatia is the principle investigator for the company’s Phase II merkel cell carcinoma clinical trial. The skin cancer is rare and aggressive.

The article, titled “Fighting skin cancer with electroimmunotherapy,” outlines the basis for OncoSec’s Phase II merkel cell carcinoma study and describes the urgent need for a new therapy for this patient population.

The article can be read by following this link: http://www.journal-newspapers.com/health-a-fitness/item/92-fighting-skin-cancer-with-electroimmunotherapy

In related news, the University of Washington and OncoSec were also featured in a news segment by the Seattle NBC affiliate news agency, KIRO 7.

OncoSec uses its electroporation delivery system which applies cell membrane stimulation to deliver immunotherapy or chemotherapy to treat a range of cancerous tumour types.

The OMS electroporation system has proven to enhance cellular uptake, effectively treating cancerous cells while sparing surrounding healthy tissue cutting through the toxic side effects of current available treatment options like chemotherapy and radiation.

In 2011, the company managed to outline a clinical development plan for its local and potentially systemic ElectroImmunotherapy program, which uses the OMS system to deliver a DNA-based immunotherapy, known as DNA IL-12.

DNA IL-12 IS designed to induce a local immune response against the treated cancerous tumour, while exploiting this response to initiate a global systemic response against untreated tumours in other areas of the body.

For the metastatic melanoma trial, a total of up to 25 patients with stage three or four cutaneous and in-transit metastatic
melanoma will be enrolled in the phase two, single-arm, open-label and multi-centre study.